RESEARCH ARTICLE
Clinical Relevance of Nanoparticle Induced Hyperthermia for Drug Delivery and Treatment of Abdominal Cancers
Nicole H. Levi-Polyachenko*, 1, John H. Stewart IV2
Article Information
Identifiers and Pagination:
Year: 2011Volume: 3
First Page: 24
Last Page: 37
Publisher Id: TONMJ-3-24
DOI: 10.2174/1875933501103010024
Article History:
Received Date: 15/06/2010Revision Received Date: 30/07/2010
Acceptance Date: 03/11/2010
Electronic publication date: 25/5/2011
Collection year: 2011
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The aim of this review is to introduce the reader to the potential clinical utility for the delivery of chemotherapy in the context of nanoparticles. We will present traditional methods of hyperthermia and then focus on the clinical technique for using intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination of colorectal cancer. Cellular mechanisms of hyperthermia as well as clinically effective chemotherapeutic agents are discussed. In the past decade carbon and metal nanoparticles have been explored for their ability to induce hyperthermia; however, many of these studies examine nanoparticles for tumor ablation at high temperatures. There are currently few studies that evaluate mild hyperthermia (below 43#x00B0;C) generated by nanoparticles to enhance the delivery of chemotherapeutic agents. The fundamentals for generation of hyperthermia from carbon and metal nanoparticles is discussed as are the limitations and benefits of specific nanoparticles with chemotherapeutic agents. This review will show that there is significant potential for the use of nanoparticles to induce hyperthermia and increase the delivery of chemotherapeutic agents for treatment of colorectal cancer and other peritoneal disease.